Nevanimibe

Cat. No.:	HY-100399
CAS No.:	133825-80-6
Molecular Formula:	$C_{27}H_{39}N_3O$
Molecular Weight:	421.62
Target:	Acyltransferase; Apoptosis
Pathway:	Metabolic Enzyme/Protease; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

Nevanimibe (PD-132301) is an orally active and selective acyl-coenzyme A:cholesterol O-acyltransferase 1 (ACAT1) inhibitor with an EC_{50} of 9 nM. Nevanimibe inhibits ACAT2 with an EC_{50} of 368 nM. Nevanimibe induces cell apoptosis and has the potential for adrenocortical cancer[1].

IC_{50} & Target

ACAT1	ACAT2
9 nM (EC50)	368 nM (EC50)

In Vitro

Coincubation of Nevanimibe (PD-132301; ATR101; 3 nM-30 μM) and Cholesterol markedly increases toxicity in a dose-dependent manner, where 3 nM Nevanimibe in the presence of 60 μg/mL Cholesterol reduces survival by 60% after 24 hours. All doses of Nevanimibe (3 nM-30 μM) induces cytoxicity in the presence of Cholesterol, whereas treatment with Cholesterol in the absence of Nevanimibe has no effect on cell viability[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay[1]

Cell Line:	The H295R and HAC clone 15 (HAC15) human ACC cell lines
Concentration:	3 nM-30 μM
Incubation Time:	24 hours
Result:	3 nM-3 μM exhibited no toxicity, whereas 30 μM treatment reduced survival by approximately 40% within 24 hours.

REFERENCES

[1]. LaPensee CR, et al. ATR-101, a Selective and Potent Inhibitor of Acyl-CoA Acyltransferase 1, Induces Apoptosis in H295R Adrenocortical Cells and in the Adrenal Cortex of Dogs. Endocrinology. 2016 May;157(5):1775-88.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA